# Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.

> **NCT00191620** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 64 (—)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00191620
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 64 (—)
- **Last updated:** 2007-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191620, "Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00191620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*